This week, in efforts to navigate malaria with treatments, prevention, and the impact of climate change, the FDA is not requesting further trials for the investigational therapy cefepime-taniborbactam, sought details on its chemistry and manufacturing controls, examining immune responses to the COVID vaccine between cancer and non-cancer patients, influence of accessibility to HCV DAA in low and middle-income countries, and a study demonstrating the efficacy of HIV ART treatment in maintaining viral load suppression.
